Xuan Zhang

Xuan Zhang

Auto-generated profile, based on publicly available information

Xuan Zhang

Department of Pharmacology, Hebei University of Chinese Medicine, Shijiazhuang, China

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2020 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
YLYingran Liang
Yingran Liang
BZBin Zheng
Bin Zheng
JLJinghan Li
Jinghan Li
JSJing Shi
Jing Shi
LCLi Chu
Li Chu
JZJianping Zhang
Jianping Zhang
Arsenic trioxide (ATO) is an excellent therapy for acute promyelocytic leukemia; however, its use is limited due to its cardiotoxicity. Crocin (CRO) possesses abundant pharmacological and biological properties, including antioxidant, anti-inflammatory, and anti-apoptotic. This study examined the cardioprotective effects of crocin and explored their mechanistic involvement in ATO-induced cardiotoxicity. Forty-eight male rats were treated with ATO to induce cardiotoxicity. In combination with ATO, CRO were given to evaluate its cardioprotection. The results demonstrated that CRO administration not only diminished QTc prolongation, myocardial enzymes and Troponin T levels but also improved histopathological results. CRO administration reduced reactive oxygen species generation. However, the CRO administration caused an increase in glutathione, superoxide dismutase, catalase, glutathione peroxidase, glutathione S-transferase and total sulphydryl levels and a decrease in malondialdehyde content, gamma glutamyl transferase and lipid hydroperoxides levels and proinflammatory cytokines. Importantly, immunohistochemical analysis, real time PCR and western blotting showed a reduction in Caspase-3 and Bcl-2-associated X protein expressions and enhancement of B cell lymphoma-2 expression. Real time PCR and western blotting showed a reduction in proinflammatory cytokines. Moreover, CRO caused an activation in nuclear factor erythroid-2 related factor 2, leading to enhanced Kelch-like ECH-associated protein 1, heme oxygenase-1 and nicotinamide adenine dinucleotide quinone dehydrogenase 1 expressions involved in Nrf2 signaling during ATO-induced cardiotoxicity. CRO was shown to ameliorate ATO-induced cardiotoxicity. The mechanisms for CRO amelioration of cardiotoxicity due to inflammation, oxidative damage, and apoptosis may occur via an up-regulated Keap1-Nrf2/HO-1 signaling pathway.

7 June 2017 in British Journal of Pharmacology
Verified
Journal Article
Closed access
PDF file
XZXuan Zhang
Xuan Zhang
HLHonglin Li
Honglin Li
HZHuiran Zhang
Huiran Zhang
YLYani Liu
Yani Liu
LHLifang Huo
Lifang Huo
WZWei ZHANG
Wei ZHANG

1 January 2019 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
QSQiongtao Song
Qiongtao Song
YZYuanyuan Zhang
Yuanyuan Zhang
XHXue Han
Xue Han
YZYing Zhang
Ying Zhang
XZXuan Zhang
Xuan Zhang
SZSenming Zhao
Senming Zhao
Salvianic acid A (SAA) is an active water-soluble constituent derived from Salvia miltiorrhiza Bge that is used extensively in the treatment of angiocardiopathy in China. However, few reports have investigated the therapeutic effect and the underlying mechanisms of SAA on atherosclerosis (AS). This study examines the protective mechanisms of SAA on AS in vivo and in vitro. SAA treatment (3 and 10 mg/kg/d) prevented the progression of atherosclerotic lesions and decreased 58.2% and 72.8% of the lipid deposition in the aorta of high fat-diet-induced AS rat. Notably, SAA treatment ameliorated serum lipid abnormalities by decreasing 20.4% and 33.8% of triglyceride, 26.1% and 32.7% of total cholesterol, 36.0% and 57.3% of low-density lipoprotein-cholesterol levels and increasing 183.4% and 337.5% of high-density lipoprotein-cholesterol level in the serum of AS rat (all P < 0.05). SAA treatment lowered pro-inflammatory mediators including interleukin-1β, interleukin-6, tumor necrosis factor-α, intercellular cell adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) (all P < 0.05) by inhibiting the toll-like receptor 4/nuclear factor kappa B pathway. In addition, SAA treatment significantly decreased oxidative stress by increasing antioxidant enzymes activity, upregulating nuclear factor erythroid 2-related factor 2/heme oxygenase-1 pathway and downregulated expression of p47phox and p22phox (all P < 0.05) in vivo. Furthermore, SAA (10-5 and 3 × 10-5 M) suppressed oxidized low-density lipoprotein-induced expression of lectin-like oxidized low-density lipoprotein receptor-1, the phosphorylation of nuclear factor kappa B (p65), ICAM-1 and VCAM-1 (all P < 0.05) and inhibited NADPH oxidase subunit 4-mediated reactive oxygen species generation in human umbilical vein endothelial cells. The experimental data verify the protective role of SAA in AS and the underlying mechanisms are strongly associated with the inhibition of oxidative stress, inflammation, and amelioration of endothelial dysfunction.

30 June 2018 in Pflügers Archiv - European Journal of Physiology
Verified
Journal Article
Closed access
PDF file
YXYucong Xue
Yucong Xue
HLHonglin Li
Honglin Li
YZYuanyuan Zhang
Yuanyuan Zhang
XHXue Han
Xue Han
GZGaohua Zhang
Gaohua Zhang
XZXuan Zhang
Xuan Zhang

5 August 2020 in Archives of Pharmacal Research
Verified
Journal Article
Closed access
PDF file
YLYingran Liang
Yingran Liang
YZYuan-Yuan Zhang
Yuan-Yuan Zhang
MLMiaomiao Liu
Miaomiao Liu
XHXue Han
Xue Han
JZJianping Zhang
Jianping Zhang
LCLi Chu
Li Chu

18 October 2024 in European Journal of Pharmacology
Verified
Journal Article
Closed access
FLFengjiao Liu
Fengjiao Liu
YJYaxin Jia
Yaxin Jia
LZLiwei Zhao
Liwei Zhao
LXLi-Na Xiao
Li-Na Xiao
XCXizhen Cheng
Xizhen Cheng
YGYunyun Geng
Yunyun Geng